Evidence map›Paper›PMID 40965719›Full record

ArticleNeurochemical research2025

Sinomenine Modifies Parkinson's Disease Through Nrf2 Activation.

Lingling Zhu, Lin Lin, Zhenyu Yang, Hongxia Tang, Jinping Wu, Zeyi Kang, Yi Feng, Binbin Zheng, Qirou Hu, Shanshan Wang and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lingling Zhu *Department of Pharmacy, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No.150, Ximen Street, Linhai, 317000, Zhejiang Province, China.
Lin Lin *Department of Pharmacy, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No.150, Ximen Street, Linhai, 317000, Zhejiang Province, China.
Zhenyu YangPublic Scientific Research Platform, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China.
Hongxia TangDepartment of Pharmacy, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No.150, Ximen Street, Linhai, 317000, Zhejiang Province, China.
Jinping WuDepartment of Pharmacy, Langzhong People's Hospital, Nanchong, Sichuan, China.
Zeyi KangDepartment of Pharmacy, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No.150, Ximen Street, Linhai, 317000, Zhejiang Province, China.
Yi FengDepartment of Neurology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China.
Binbin ZhengDepartment of Orthopaedics, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China.
Qirou HuDepartment of Pharmacy, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No.150, Ximen Street, Linhai, 317000, Zhejiang Province, China.
Shanshan WangDepartment of Neurology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China.
Cuimin LiuDepartment of Pharmacy, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No.150, Ximen Street, Linhai, 317000, Zhejiang Province, China.
Zhengli JiangDepartment of Pharmacy, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No.150, Ximen Street, Linhai, 317000, Zhejiang Province, China.
Suzhi LiuDepartment of Neurology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China.
Gang WuDepartment of Pharmacy, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No.150, Ximen Street, Linhai, 317000, Zhejiang Province, China. weichen_star@126.com.

Funding

National Natural Science Foundations of China 81903584Taizhou Science and Technology Plan Project 20ywb06Zhejiang Provincial Basic and Public Welfare Research Program LGD20H310002Zhejiang Provincial Basic and Public Welfare Research Program LGF20H090009
6 · The paper itself

Abstract

backgroundDisease-modifying treatments for Parkinson's disease (PD) are urgently needed, with the Nrf2/ARE pathway a promising target. This study aims to explore the effects of sinomenine on PD and Nrf2/ARE activation.

methods6-OHDA-treated Parkinsonian SH-SY5Y cells and rats were used. Apoptosis and cell viability were measured using flow cytometry and CCK-8 assays. Nrf2 and its downstream proteins were assessed by Western blotting, while ROS levels were detected with fluorescent dyes. Nrf2 silencing via shRNA evaluated sinomenine's dependence on Nrf2 activation. In vivo, behavioral changes, tyrosine hydroxylase (TH) levels and malondialdehyde (MDA) levels were measured. Microglial inflammation was analyzed by measuring TNF-α and IL-1β expression and cytoskeleton analysis. Nrf2 nuclear translocation was verified by Western blotting and molecular docking was performed.

resultsSinomenine reduced apoptosis and ROS, improved cell viability, upregulated Nrf2 and antioxidant enzyme expression. The protective effects against apoptosis were abolished by Nrf2 silencing. In PD animals, sinomenine improved motor deficits, enhanced Nrf2, GCLC, GCLM, NQO1, and HO-1 expression, decreased MDA levels, increased TH levels in the striatum and maintained count of dopaminergic neurons in substantia nigra. Additionally, it suppressed TNF-α and IL-1β levels in brain tissue and blood, preserving normal microglial morphology and reducing neuroinflammation. Sinomenine promoted Nrf2 nuclear translocation and showed high Keap1 affinity in docking.

conclusionsSinomenine activates the Nrf2/ARE pathway, mitigating oxidative stress and inflammation in PD models, possibly through Keap1 binding and Nrf2 nuclear translocation. These findings suggest sinomenine may serve as a potential disease-modifying therapy for Parkinson's disease, pending further clinical validation.

Indexed as

MorphinansNF-E2-Related Factor 2Parkinson DiseaseAnimalsApoptosisCell Line, TumorCell SurvivalHumansMaleMolecular Docking SimulationOxidative StressOxidopamineRatsRats, Sprague-DawleySignal TransductionMorphinansNFE2L2 protein, humanNfe2l2 protein, ratNF-E2-Related Factor 2OxidopaminesinomenineDisease-modifyingNrf2/ARENuclear translocationParkinson’s diseaseSinomenine

Identifiers

PMID40965719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.